ArticleJournal of neuro-oncology2014
Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib.
Article in Journal of neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review.JAMA oncology · 2015Pooled it
- Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles.Neuro-oncology advances · 2021Article
- Article
- Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF.JCO precision oncology · 2021Article
- Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases.Science translational medicine · 2020Article
- Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors - Results of a Prospective Biomarker Study.OncoTargets and therapy · 2020Article
- Concurrent Radiosurgery and Systemic Therapies for Melanoma Brain Metastases: A Systematic Review.Cureus · 2019Review
- The Impact of Targeted Therapy on Intracranial Metastatic Disease Incidence and Survival.Frontiers in oncology · 2019Article
- Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges.American journal of clinical dermatology · 2018Review
- Predicting the incidence and timing of central nervous system disease in metastatic melanoma: Implications for surveillance and preventative therapy.Journal of the American Academy of Dermatology · 2018Article
- Article
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma.OncoTargets and therapy · 2018Review
- Targeted therapy of brain metastases: latest evidence and clinical implications.Therapeutic advances in medical oncology · 2017Review
- Review
- Brain metastases from hepatocellular carcinoma: recent advances and future avenues.Oncotarget · 2017Review
- Targeted Therapies for Melanoma Brain Metastases.Current treatment options in neurology · 2017Review
- Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Neuro-oncology · 2017Review
- Challenges in the delivery of therapies to melanoma brain metastases.Current pharmacology reports · 2016Article
- [Melanoma brain metastases : Treatment options].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2016Review
- Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors.Targeted oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vemurafenib is indicated for the treatment of patients with BRAF (V600)-mutant metastatic melanoma. We studied for the first time the characteristics of brain metastases developed during treatment with vemurafenib in real-life conditions. We included all patients treated over 3 years with vemurafenib in our department for metastatic melanoma without initial brain involvement. Our primary endpoint was to assess the incidence of brain metastases in these patients. Our secondary endpoints were to identify the risk factors for metastases occurrence and their characteristics and course. In our retrospective cohort of 86 patients, 20% had developed brain metastases on average 5.3 months after vemurafenib initiation. The median follow-up was 9 months (1-26 months). Radiological examinations revealed multiple brain metastases in 41% of patients. The only risk factor for metastasis occurrence identified was a high number of metastatic sites when initiating vemurafenib (p = 0.045). Metastasis development was associated with a trend toward a decrease in overall survival from 12.8 to 8.5 months (p = 0.07) and a significant decrease in progression-free survival from 7 to 5 months (p = 0.04). Among the patients who developed brain metastases, 82% died, of whom 64% within 3 months, versus 58% of patients without brain metastases over the same period. The extra-cerebral disease was well controlled in 59% of patients during brain progression. In vemurafenib-treated melanoma patients, brain metastases are frequent and associated with a particularly poor prognosis. Because of their high frequency in patients with controlled extra-cerebral disease, brain explorations should be systematically performed during treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.